Overview

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Status:
Completed

Trial end date:
2018-10-31

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to compare the effect of daily oral administration of elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo in patients with PBC and inadequate response to Ursodeoxycholic acid (UDCA).

Phase:

Phase 2

Details

Lead Sponsor:

Genfit

Treatments:

Ursodeoxycholic Acid